Pharmakogenetische Testungen zur Optimierung der
                    Psychopharmakotherapie: Patient mit schwerer Depression und ausbleibendem
                    Therapieerfolg aufgrund von Polymorphismen im CYP2D6- und
                    CYP2C19-Gen

Andreas Philipp Eckert; Martina Hahn

doi:10.1055/a-2405-5037

Fortschritte der Neurologie · Psychiatrie, Inhaltsverzeichnis

Fortschr Neurol Psychiatr
DOI: 10.1055/a-2405-5037

Der interessante Fall

Pharmakogenetische Testungen zur Optimierung der Psychopharmakotherapie: Patient mit schwerer Depression und ausbleibendem Therapieerfolg aufgrund von Polymorphismen im CYP2D6- und CYP2C19-Gen

Pharmacogenetic testing to optimize psychopharmacotherapy: Case study of a patient with severe depression and lack of treatment success due to genetic polymorphisms for CYP2D6 and CYP2C19

Andreas Philipp Eckert

¹Klinik für Psychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Frankfurt Klinik für Psychiatrie, Frankfurt am Main, Germany (Ringgold ID: RIN163233)

,

Martina Hahn

¹Klinik für Psychiatrie, Psychosomatik und Psychotherapie, Universitätsklinikum Frankfurt Klinik für Psychiatrie, Frankfurt am Main, Germany (Ringgold ID: RIN163233)

²Klinik für psychische Gesundheit, varisano Klinikum Frankfurt Hoechst, Frankfurt, Germany

Literatur
1 Rush AJ, Trivedi MH, Wisniewski SR. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-1917
2 Arranz MJ, Gonzalez-Rodriguez A, Perez-Blanco J. et al. A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments. Transl Psychiatry 2019; 25 9 177
3 Hampton LM, Daubresse M, Chang H-Y. et al. Emergency department visits by adults for psychiatric medication adverse events. JAMA Psychiatry 2014; 71: 1006-1014
4 Bull SA, Hunkeler EM, Lee JY. et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Annals of Pharmacotherapy 2002; 36: 578-584
5 Hicks JK, Bishop JR, Sangkuhl K. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther 2015; 98: 127-134
6 van Westrhenen R, Aitchison KJ, Ingelman-Sundberg M. et al. Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?. Frontiers in Psychiatry 2020; 12: 94
7 Fleeman N, Dundar Y, Dickson R. et al. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. The Pharmacogenomics Journal 2011; 11: 1-14
8 Bousman CA, Stevenson JM, Ramsey LB. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther 2023; 114: 51-68
9 Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharm Ther 2011; 89: 464-467
10 Swen JJ, Nijenhuis M, de Boer A. et al. Pharmacogenetics: from bench to byte – an update of guidelines. Clin Pharmacol Ther 2011; 89: 662-673
11 Lunenburg CATC GasseC. Pharmacogenetics in psychiatric care, a call for uptake of available applications. Psychiatry Res 2020; 292: 113336
12 Ahmed S, Tahir R, Akhtar U. et al. Pharmacogenomics Guided Prescription Changes Improved Medication Effectiveness in Patients With Mental Health-Related Disability: A Retrospective Cohort Analyses. Front Genet 2021; 12: 644694
13 Papastergiou J, Quilty LC, Li W. et al. Pharmacogenomics guided versus standard antidepressant treatment in a community pharmacy setting: A randomized controlled trial. Clin Transl Sci 2021; 14: 1359-1368
14 Brown LC, Stanton JD, Bharthi K. et al. Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta-Analysis of Prospective, Controlled Clinical Trials. Clinical Pharmacology and Therapeutics 2022; 112: 1303-1317
15 Swen JJ, van der Wouden CH, En Manson L. et al. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study. Lancet 2023; 401: 347-356
16 Bousman CA, Arandjelovic K, Mancuso SG. et al. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics 2019; 20: 37-47
17 Vegter S, Boersma C, Rozenbaum M. et al. Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines. Pharmacoeconomics 2008; 26: 569-587
18 Tanner J-A, Davies PE, Overall CC. et al. Cost-effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspective. Pharmacogenomics 2020; 21: 521-531
19 Hahn M, Müller DJ, Roll SC. Frequencies of Genetic Polymorphisms of Clinically Relevant Gene-Drug Pairs in a German Psychiatric Inpatient Population. Pharmacopsychiatry 2021; 54: 81-89
20 Bättig VAD, Roll SC, Hahn M. Pharmacogenetic Testing in Depressed Patients and Interdisciplinary Exchange between a Pharmacist and Psychiatrists Results in Reduced Hospitalization Times. Pharmacopsychiatry 2020; 53: 185-192
21 Eckert A, Frantz A, Scherf-Clavel M. et al Divergent Phenotypes, Actionable Genotypes, and Phenoconversion in a German Psychiatric Inpatient Population: Results from the FACT-PGx Study. J Explor Res Pharmacol. Published online Feb 9 2024;
22 Eckert A, Frantz A, Reif A. et al. Akzeptanz, Wissen und Einstellungen von Ärzten zu pharmakogenetischen Tests in der Psychiatrie. Nervenheilkunde 2023; 42: 459-466
23 Stäuble CK, Jeiziner C, Bollinger A. et al. A Guide to a Pharmacist-Led Pharmacogenetic Testing and Counselling Service in an Interprofessional Healthcare Setting. Pharmacy (Basel) 2022; 10: 86
24 Hiemke C, Bergemann N, Clement HW. et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51: 9-62
25 Hicks JK, Sangkuhl K, Swen JJ. et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther 2017; 102: 37-44
26 Hahn M, Frantz AM, Eckert A. et al. Barrieren bei der Implementierung pharmakogenetischer Testungen in der Psychiatrie in Deutschland - Ergebnisse aus der FACT-PGx Studie. Fortschritte in Neurologie und Psychiatrie 2023;